ACE-话题@MedSci

#ACE#

496篇内容 | 3856人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1656125, encodeId=a9b61656125ec, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, objectType=article, longId=739183, objectId=460ce39183f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460ce39183f7, replyNumber=0, likeNumber=175, createdTime=2023-07-06, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460ce39183f7, moduleTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460ce39183f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656117, encodeId=2901165611e6e, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=新研究发现，ACEI 和 ARB 降低糖尿病肾病患者终末期肾病的发病率, objectType=article, longId=737427, objectId=d9dae374275d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9dae374275d, replyNumber=0, likeNumber=128, createdTime=2022-09-30, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9dae374275d, moduleTitle=新研究发现，ACEI 和 ARB 降低糖尿病肾病患者终末期肾病的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9dae374275d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656115, encodeId=851e1656115a8, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=European Radiology：基于AI的全自动脾分割在肝癌TACE患者风险分层中的应用, objectType=article, longId=735918, objectId=d69de35918fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d69de35918fd, replyNumber=0, likeNumber=112, createdTime=2023-01-05, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d69de35918fd, moduleTitle=European Radiology：基于AI的全自动脾分割在肝癌TACE患者风险分层中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d69de35918fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656113, encodeId=06f91656113c1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=J AM COLL RADIOL：肝癌TACE术后该选择何种药物进行疼痛控制？, objectType=article, longId=731865, objectId=d093e3186597, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d093e3186597, replyNumber=0, likeNumber=123, createdTime=2022-07-25, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d093e3186597, moduleTitle=J AM COLL RADIOL：肝癌TACE术后该选择何种药物进行疼痛控制？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d093e3186597)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656118, encodeId=11ac165611824, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=“神药”再发威！助力肝癌TACE后缓解，还能降低局部复发风险达72%！, objectType=article, longId=737564, objectId=6b6de3756448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b6de3756448, replyNumber=0, likeNumber=127, createdTime=2022-12-07, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b6de3756448, moduleTitle=“神药”再发威！助力肝癌TACE后缓解，还能降低局部复发风险达72%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b6de3756448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656103, encodeId=116a165610354, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=DOM:2型糖尿病患者早期和持续稳定的血糖控制与主要不良心血管事件(MACE)的减少相关, objectType=article, longId=724839, objectId=0f64e24839a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f64e24839a9, replyNumber=0, likeNumber=128, createdTime=2022-12-18, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f64e24839a9, moduleTitle=DOM:2型糖尿病患者早期和持续稳定的血糖控制与主要不良心血管事件(MACE)的减少相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f64e24839a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656123, encodeId=8d0a165612398, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Chest：通过 PAH 中的活动记录评估日常生活中的身体活动：来自司来帕格 (TRACE) 随机对照研究的见解, objectType=article, longId=739329, objectId=e177e3932903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e177e3932903, replyNumber=0, likeNumber=161, createdTime=2023-03-08, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e177e3932903, moduleTitle=Chest：通过 PAH 中的活动记录评估日常生活中的身体活动：来自司来帕格 (TRACE) 随机对照研究的见解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e177e3932903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656102, encodeId=8bf216561027a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, objectType=article, longId=724127, objectId=b5ebe2412785, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5ebe2412785, replyNumber=0, likeNumber=129, createdTime=2023-01-30, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5ebe2412785, moduleTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5ebe2412785)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656121, encodeId=65ec1656121cc, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, objectType=article, longId=739075, objectId=1b78e39075cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b78e39075cc, replyNumber=0, likeNumber=117, createdTime=2023-05-22, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b78e39075cc, moduleTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b78e39075cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656100, encodeId=bd2916561008a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Europace：口服抗凝治疗对心房颤动患者虚弱症状与临床结局的影响分析, objectType=article, longId=300533, objectId=c9cf3005336f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9cf3005336f, replyNumber=0, likeNumber=128, createdTime=2022-09-30, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9cf3005336f, moduleTitle=Europace：口服抗凝治疗对心房颤动患者虚弱症状与临床结局的影响分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9cf3005336f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656105, encodeId=b9f716561059d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, objectType=article, longId=726291, objectId=eddae262914c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eddae262914c, replyNumber=0, likeNumber=121, createdTime=2023-04-03, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eddae262914c, moduleTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eddae262914c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656093, encodeId=6079165609366, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Hypertension：注意了——DPP4抑制剂和ACEI联用易出现这种副作用！, objectType=article, longId=294699, objectId=1364294699cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1364294699cd, replyNumber=0, likeNumber=0, createdTime=2022-10-08, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1364294699cd, moduleTitle=Hypertension：注意了——DPP4抑制剂和ACEI联用易出现这种副作用！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1364294699cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656114, encodeId=b8201656114fd, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Cardiovasc Diabetol：糖化ACE2可降低糖尿病患者心脏中RAS系统抑制的抗重构作用, objectType=article, longId=735303, objectId=ae19e3530333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae19e3530333, replyNumber=0, likeNumber=128, createdTime=2022-10-18, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae19e3530333, moduleTitle=Cardiovasc Diabetol：糖化ACE2可降低糖尿病患者心脏中RAS系统抑制的抗重构作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae19e3530333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656119, encodeId=abb816561195f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=【每日播报】-对于伴MAU的高血压和（或）糖尿病患者首选ACEI或ARB治疗, objectType=article, longId=737689, objectId=0477e3768950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0477e3768950, replyNumber=0, likeNumber=95, createdTime=2023-02-10, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0477e3768950, moduleTitle=【每日播报】-对于伴MAU的高血压和（或）糖尿病患者首选ACEI或ARB治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0477e3768950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656095, encodeId=5a7516560958a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Nature Communications：超能力！ACE2受体蛋白“纳米囊泡”可防治新冠, objectType=article, longId=295475, objectId=583c2954e5a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=583c2954e5a1, replyNumber=0, likeNumber=124, createdTime=2022-03-14, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=583c2954e5a1, moduleTitle=Nature Communications：超能力！ACE2受体蛋白“纳米囊泡”可防治新冠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=583c2954e5a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656101, encodeId=f898165610101, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=European Radiology：CCTA预测斑块进展和主要不良心脏事件(MACE)究竟有何优点和挑战？, objectType=article, longId=300781, objectId=d915300e8164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d915300e8164, replyNumber=0, likeNumber=128, createdTime=2022-11-10, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d915300e8164, moduleTitle=European Radiology：CCTA预测斑块进展和主要不良心脏事件(MACE)究竟有何优点和挑战？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d915300e8164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656111, encodeId=44eb16561113b, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Stroke：症状性颈动脉狭窄患者血小板粘附抑制剂Revacept的疗效, objectType=article, longId=729284, objectId=02a9e29284cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02a9e29284cb, replyNumber=0, likeNumber=137, createdTime=2023-05-23, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02a9e29284cb, moduleTitle=Stroke：症状性颈动脉狭窄患者血小板粘附抑制剂Revacept的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02a9e29284cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656098, encodeId=2315165609812, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, objectType=article, longId=299277, objectId=87e42992e798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87e42992e798, replyNumber=0, likeNumber=0, createdTime=2022-08-13, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87e42992e798, moduleTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87e42992e798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656124, encodeId=73bf1656124b2, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=ACEI和ARB不仅降压，还可能降低急性呼吸衰竭患者院内死亡率, objectType=article, longId=739295, objectId=824ee3929543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=824ee3929543, replyNumber=0, likeNumber=127, createdTime=2023-07-31, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=824ee3929543, moduleTitle=ACEI和ARB不仅降压，还可能降低急性呼吸衰竭患者院内死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=824ee3929543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656116, encodeId=cc601656116e1, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关, objectType=article, longId=736018, objectId=8b06e36018f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b06e36018f7, replyNumber=0, likeNumber=123, createdTime=2023-07-10, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b06e36018f7, moduleTitle=European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b06e36018f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ACE

2020-05-29

shanyongle

#ACE#

Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤

2023-07-06

shanyongle

#ACE#

新研究发现，ACEI 和 ARB 降低糖尿病肾病患者终末期肾病的发病率

2022-09-30

shanyongle

#ACE#

European Radiology：基于AI的全自动脾分割在肝癌TACE患者风险分层中的应用

2023-01-05

shanyongle

#ACE#

J AM COLL RADIOL：肝癌TACE术后该选择何种药物进行疼痛控制？

2022-07-25

shanyongle

#ACE#

“神药”再发威！助力肝癌TACE后缓解，还能降低局部复发风险达72%！

2022-12-07

shanyongle

#ACE#

DOM:2型糖尿病患者早期和持续稳定的血糖控制与主要不良心血管事件(MACE)的减少相关

2022-12-18

shanyongle

#ACE#

Chest：通过 PAH 中的活动记录评估日常生活中的身体活动：来自司来帕格 (TRACE) 随机对照研究的见解

2023-03-08

shanyongle

#ACE#

Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据

2023-01-30

shanyongle

#ACE#

ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）

2023-05-22

shanyongle

#ACE#

Europace：口服抗凝治疗对心房颤动患者虚弱症状与临床结局的影响分析

2022-09-30

shanyongle

#ACE#

Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据

2023-04-03

hb2008ye

#ACE#

Hypertension：注意了——DPP4抑制剂和ACEI联用易出现这种副作用！

2022-10-08

shanyongle

#ACE#

Cardiovasc Diabetol：糖化ACE2可降低糖尿病患者心脏中RAS系统抑制的抗重构作用

2022-10-18

shanyongle

#ACE#

【每日播报】-对于伴MAU的高血压和（或）糖尿病患者首选ACEI或ARB治疗

2023-02-10

shanyongle

#ACE#

Nature Communications：超能力！ACE2受体蛋白“纳米囊泡”可防治新冠

2022-03-14

shanyongle

#ACE#

European Radiology：CCTA预测斑块进展和主要不良心脏事件(MACE)究竟有何优点和挑战？

2022-11-10

shanyongle

#ACE#

Stroke：症状性颈动脉狭窄患者血小板粘附抑制剂Revacept的疗效

2023-05-23

shanyongle

#ACE#

Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS

2022-08-13

shanyongle

#ACE#

ACEI和ARB不仅降压，还可能降低急性呼吸衰竭患者院内死亡率

2023-07-31

shanyongle

#ACE#

European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关

2023-07-10

科室
- - 订阅+
  - 更多科室
工具
服务